rs137852581
|
|
|
0.020 |
GeneticVariation |
BEFREE |
SfaNI digestion of AR exon H DNA from normal but not from prostate cancer tissue indicated H874Y is a somatic mutation that occurred before the initial tumor transplant.
|
9092797 |
1997 |
rs137852593
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The present study indicates that the R726L substitution in the AR may confer an up to 6-fold increased risk of prostate cancer and may contribute to cancer development in up to 2% of Finnish prostate cancer patients.
|
11103816 |
2000 |
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Conversely, no association was observed between prostate carcinoma risk and the other polymorphisms studied as follow: the CAG repeat in exon 1 of AR, the (TA)n dinucleotide repeat polymorphism in the 3' untranslated region, and the A49T or V89L substitutions in SDR5A2, the single base pair (bp) (a T to C transition) polymorphism that creates an additional Sp1-type (CCACC box) promoter site in CYP17.
|
11571725 |
2001 |
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Conversely, no association was observed between prostate carcinoma risk and the other polymorphisms studied as follow: the CAG repeat in exon 1 of AR, the (TA)n dinucleotide repeat polymorphism in the 3' untranslated region, and the A49T or V89L substitutions in SDR5A2, the single base pair (bp) (a T to C transition) polymorphism that creates an additional Sp1-type (CCACC box) promoter site in CYP17.
|
11571725 |
2001 |
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al.Nature Med.2000, 6, 703-6).
|
11906285 |
2002 |
rs864622007
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al.Nature Med.2000, 6, 703-6).
|
11906285 |
2002 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The cortisol/cortisone-responsive AR (AR(ccr)) has two mutations (L701H and T877A) that were found in the MDA PCa human prostate cancer cell lines established from a castrated patient whose metastatic tumor exhibited androgen-independent growth.
|
11956172 |
2002 |
rs864622007
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The cortisol/cortisone-responsive AR (AR(ccr)) has two mutations (L701H and T877A) that were found in the MDA PCa human prostate cancer cell lines established from a castrated patient whose metastatic tumor exhibited androgen-independent growth.
|
11956172 |
2002 |
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
rs137852571
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In prostate cancer DU-145 cells, which were transiently transfected with CBP cDNA, hydroxyflutamide enhanced AR activity to a greater extent than bicalutamide in the presence of either wild-type or the mutated AR 730 val-->met.
|
12507906 |
2003 |
rs137852593
|
|
|
0.040 |
GeneticVariation |
BEFREE |
R726L androgen receptor mutation is uncommon in prostate cancer families in the united states.
|
12539229 |
2003 |
rs137852593
|
|
|
0.040 |
GeneticVariation |
BEFREE |
To estimate the possible involvement of the prostate cancer predisposing AR Arg726Leu germ-line mutation in MBC, this mutation was tested in 117 MBC patients.
|
12602915 |
2003 |
rs137852593
|
|
|
0.040 |
GeneticVariation |
BEFREE |
R726L substitution in the hormone binding region of androgen receptor was found in 1 prostate cancer family but no previously uncharacterized germline mutations were detected.
|
14665948 |
2004 |
rs976306779
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A link between elevated IL6 and up-regulated S100P in androgen-refractory and metastatic PCa is postulated.
|
15474988 |
2005 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The T877A mutant of the AR frequently found in advanced cases of prostate cancer displays an exaggerated stimulation of transcriptional activity by CDK6.
|
15790678 |
2005 |
rs968098233
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Although the vast majority of AR mutations appeared capable of increased activation in response to ART-27, an AR mutation identified in prostate cancer (AR P340L) and AIS (AR E2K) show reduced transcriptional responses to ART-27, whereas their response to the p160 class of coactivators was not diminished.
|
15919721 |
2005 |
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Taken together, these findings provide novel insights into the AR dysfunctions resulting from the T877A mutation and functionally similar AR alterations may provide selective cell growth/survival advantage for CaP progression.
|
16636679 |
2006 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutation (T877A) of the AR gene found in an androgen-sensitive prostate cancer cell line, LNCaP, has been postulated to be involved in hypersensitivity and loss of specificity for androgen.
|
17312014 |
2007 |
rs137852581
|
|
|
0.020 |
GeneticVariation |
BEFREE |
T can nevertheless acquire DHT-like activity through an AR helix-10 H874Y prostate cancer mutation.
|
17591767 |
2007 |
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The androgen-mediated repression of hTERT is abrogated in a human prostate cancer cell line exhibiting hormone-dependent growth, which expresses a mutant AR (T877A) frequently occurring in prostate cancer.
|
17991730 |
2008 |